Dr. Ander Matheu Fernandez
My Social Links

Dr. Ander Matheu Fernandez

Research Director
Biodonostia Institute, Spain

Highest Degree
PostDoc Fellow in Stem Cell Biology from Medical Research Council, Gambia, UK

Share this Profile

Biography

Dr. Ander Matheu Fernandez is currently working as Cellular Oncology Group Leader at Oncology Department, Biodonostia Institute San Sebastian, Spain. He has completed his PhD in Molecular Biology from Universidad Autonoma, Madrid (Spain), and Postdoctoral fellow at Molecular Oncology Program, Spanish National Cancer Center (CNIO), Madrid, Spain. Previously he was appointed as Postdoctoral Research Scientist at Developmental Genetics Division, MRC National Institute for Medical Research (NIMR), London, UK. Dr. Ander received honours includes M-AES motility fellowship award, Aging Cell best paper prize for 2009, Best poster award in Stem Cells and Cancer meeting and many others. He also participated in 15 funded research projects. Dr. Ander has published 30 research articles in journal and 1 book chapter. He has successfully supervised/co-supervised number of PhD and masters students’ thesis. He also attended number of scientific meeting and performed presentation. Dr. Ander is also serving as member of Spanish Society of Geriatry and Gerontology, and Spanish Group of Centenarians Research. Dr. Ander is member of editorial board for Oncology Case Reports and American Journal of Cancer Research.

Area of Interest:

Biomedical Sciences
100%
Oncology
62%
Stem Cells
90%
Aging
75%
Neurology
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
26
Abstracts
0

Selected Publications

  1. Garros-Regulez, L., P. Aldaz, O. Arrizabalaga, V. Moncho-Amor and E. Carrasco-Garcia et al., 2016. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin. Ther. Targets, 20: 393-405.
    CrossRef  |  PubMed  |  Direct Link  |  
  2. Carrasco-Garcia, E., J.C. Santos, I. Garcia, M. Brianti and M. Garcia-Puga et al., 2016. Paradoxical role of SOX2 in gastric cancer. Am. J. Cancer Res., 6: 701-713.
    Direct Link  |  
  3. Yaswen, P., K.L. MacKenzie, W.N. Keith, P. Hentosh and F. Rodier et al., 2015. Therapeutic targeting of replicative immortality. Semin. Cancer Biol., Vol. 35. 10.1016/j.semcancer.2015.03.007.
    CrossRef  |  PubMed  |  Direct Link  |  
  4. Okamoto, O.K., A. Matheu and L. Magnani, 2015. Stem cells in translational cancer research. Stem Cells Int., Vol. 2015. 10.1155/2015/281072.
    CrossRef  |  PubMed  |  Direct Link  |  
  5. Mateos-Aierdi, A.J., M. Goicoechea, A. Aiastui, R. Fernandez-Torron, M. Garcia-Puga, A. Matheu and A.L. de Munain, 2015. Muscle wasting in myotonic dystrophies: A model of premature aging. Front. Aging Neurosci., Vol. 7. 10.3389/fnagi.2015.00125.
    CrossRef  |  PubMed  |  Direct Link  |  
  6. Carrasco-Garcia, E., O. Arrizabalaga, M. Serrano, R. Lovell-Badge and A. Matheu, 2015. Increased gene dosage of Ink4/Arf and p53 delays age-associated central nervous system functional decline. Aging Cell, 14: 710-714.
    CrossRef  |  PubMed  |  Direct Link  |  
  7. Sanchez, Y., V. Segura, O. Marin-Bejar, A. Athie and F.P. Marchese et al., 2014. Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat. Commun., Vol. 5. 10.1038/ncomms6812.
    CrossRef  |  PubMed  |  Direct Link  |  
  8. Manterola, L., E. Guruceaga, J.G. Perez-Larraya, M. Gonzalez-Huarriz and P. Jauregui et al., 2014. A sncRNA signature found in microvesicles of GBM patient serum serves as a diagnostic marker. Neurooncol., 16: 520-527.
  9. Etxaniz, U., A.P.S. Vicente, N. Gago-Lopez, M. Garcia-Dominguez and H. Iribar et al., 2014. Neural-competent cells of adult human dermis belong to the Schwann lineage. Stem Cell Rep., 3: 774-788.
    CrossRef  |  PubMed  |  Direct Link  |  
  10. De la Rocha, A.M., N. Sampron, M.M. Alonso and A. Matheu, 2014. Role of SOX family of transcription factors in central nervous system tumors. Am. J. Cancer Res., 4: 312-324.
    Direct Link  |  
  11. Carrasco-Garcia, E., N. Sampron, P. Aldaz, O. Arrizabalaga and J. Villanua et al., 2013. Therapeutic strategies targeting glioblastoma stem cells. Recent Pat. Anti-Cancer Drug Discovery, 8: 216-227.
    PubMed  |  Direct Link  |  
  12. Matheu, A., M. Collado, C. Wise, L. Manterola and L. Cekaite et al., 2012. Oncogenicity of the developmental transcription factor Sox9. Cancer Res., 72: 1301-1315.
    CrossRef  |  PubMed  |  Direct Link  |  
  13. Li, H., M. Collado, A. Villasante, A. Matheu and C.J. Lynch et al., 2012. p27kip1 directly represses SOX2 during embryonic stem cell differentiation. Cell Stem Cell, 11: 845-852.
    CrossRef  |  Direct Link  |  
  14. Gomez-Gaviro, M.V., C.E. Scott, A.K. Sesay, A. Matheu, S. Booth, C. Galichet and R. Lovell-Badge, 2012. Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis. Proc. Natl. Acad. Sci., 109: 1317-1322.
    CrossRef  |  PubMed  |  Direct Link  |  
  15. Castillo, S.D., A. Matheu, N. Mariani, J. Carretero, F. Lopez-Rios, R. Lovell-Badge and M. Sanchez-Cespedes, 2011. Novel transcriptional targets of the SRY-HMG box transcription factor SOX4 link its expression to the development of small cell lung cancer. Cancer Res., 72: 176-186.
    CrossRef  |  Direct Link  |  
  16. Acloque, H., O.H. Ocana, A. Matheu, K. Rizzoti, C. Wise, R. Lovell-Badge and M.A. Nieto, 2011. Reciprocal repression between Sox3 and snail transcription factors defines embryonic territories at gastrulation. Dev. Cell, 21: 546-558.
    CrossRef  |  PubMed  |  Direct Link  |  
  17. Matheu, A., A. Maraver, M. Collado, I. Garcia-Cao and M. Canamero et al., 2009. Anti-aging activity of the Ink4/Arf locus. Aging Cell, 8: 152-161.
    CrossRef  |  Direct Link  |  
  18. Tomas-Loba, A., I. Flores, P.J. Fernandez-Marcos, M.L. Cayuela and A. Maraver et al., 2008. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell, 135: 609-622.
    CrossRef  |  PubMed  |  Direct Link  |  
  19. Matheu, A., A. Maraver and M. Serrano, 2008. The Arf/p53 pathway in cancer and aging. Cancer Res., 68: 6031-6034.
    CrossRef  |  PubMed  |  Direct Link  |  
  20. Matheu, A., A. Maraver, P. Klatt, I. Flores and I. Garcia-Cao et al., 2007. Delayed ageing through damage protection by the Arf/p53 pathway. Nat., 448: 375-379.
    CrossRef  |  PubMed  |  Direct Link  |  
  21. Zeini, M., P.G. Traves, R. Lopez-Fontal, C. Pantoja and A. Matheu et al., 2006. Specific contribution of p19ARF to nitric oxide-dependent apoptosis. J. Immunol., 177: 3327-3336.
    CrossRef  |  PubMed  |  Direct Link  |  
  22. Garcia, M.A., M. Collado, C. Munoz-Fontela, A. Matheu and L. Marcos-Villar et al., 2006. Antiviral action of the tumor suppressor ARF. Embo J., 25: 4284-4292.
    CrossRef  |  PubMed  |  Direct Link  |  
  23. Pantoja, C., L. de los Rios, A. Matheu, F. Antequera and M. Serrano, 2005. Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res., 65: 26-33.
    PubMed  |  Direct Link  |  
  24. Matheu, A., P. Klatt and M. Serrano, 2005. Regulation of the INK4a/ARF locus by histone deacetylase inhibitors. J. Biol. Chem., 280: 42433-42441.
    CrossRef  |  PubMed  |  Direct Link  |  
  25. Lavado, A., A. Matheu, M. Serrano and L. Montoliu, 2005. A strategy to study tyrosinase transgenes in mouse melanocytes. BMC Cell Biol., Vol. 6. 10.1186/1471-2121-6-18.
    CrossRef  |  PubMed  |  Direct Link  |  
  26. Matheu, A., C. Pantoja, A. Efeyan, L.M. Criado and J. Martin-Caballero et al., 2004. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev., 18: 2736-2746.
    CrossRef  |  PubMed  |  Direct Link  |